ArticleFrontiers in endocrinology2026
Case Report: Recurrent abdominal pain with elevated pancreatic enzymes in type 2 diabetes mellitus: a case of IgG4-related autoimmune pancreatitis misdiagnosed as acute pancreatitis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgG4-related autoimmune pancreatitis (IgG4-AIP) is a rare autoimmune pancreatic disorder with non-specific clinical manifestations that is often misdiagnosed as acute pancreatitis (AP). Its coexistence with type 2 diabetes mellitus (T2DM) may further complicate recognition of the underlying pancreatic disease. Case presentation: A 60-year-old male with a 4-year history of T2DM was admitted for diabetic complications manifesting as blurred vision and lower limb numbness. During hospitalization, he developed recurrent epigastric pain associated with elevated pancreatic enzymes and was initially diagnosed with AP. Conventional treatment for AP did not lead to sustained improvement, and amylase and lipase remained persistently elevated. Serum IgG4 was markedly elevated at 13.8 g/L. Imaging findings were unremarkable. Endoscopic ultrasound-guided fine-needle aspiration revealed chronic inflammatory changes. The diagnosis of IgG4-AIP was ultimately established based on the markedly elevated serum IgG4 level, supportive (though atypical) imaging findings, histopathological features, and a favorable response to glucocorticoid therapy. The patient's symptoms improved, accompanied by an overall decrease in serum IgG4 and pancreatic enzyme levels. Conclusion: In T2DM patients with recurrent abdominal pain and persistently elevated pancreatic enzymes unresponsive to routine AP treatment, IgG4-AIP should be considered. Timely measurement of serum IgG4 and careful integration of imaging, histopathology, and treatment response are important for early diagnosis. Early recognition may prevent misdiagnosis and enable timely initiation of glucocorticoid therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.